Hydroxyapatite Was Invented by NASA: The Surprising Origin Story

Last updated: July 2026. Reviewed against NASA's official Spinoff publication, historical toothpaste industry sources, and current clinical hydroxyapatite literature

Most ingredient stories in oral care are forgettable. This one genuinely is not, and it happens to be true, which is rarer than it should be in this category. It involves a semiconductor lab, an unused patent, an astronaut health crisis, and a Japanese entrepreneur combing through government paperwork looking for his next opportunity. Here is what actually happened, told with the nuance the popular version usually leaves out.

The Real Problem: Astronauts Losing Bone and Teeth in Space

The story only makes sense once you understand the actual medical crisis NASA was facing in the early years of long duration spaceflight. Without gravity pressing down on the skeleton, bones stop receiving the mechanical stress signal that normally tells the body to maintain bone density. The first detailed observations, made in the mid 1970s, found that astronauts were losing bone mass at a rate of roughly 1 to 2 percent per month, a speed of loss dramatically faster than anything seen from ordinary aging on Earth. The loss concentrated in weight bearing bones, the hips, spine, and legs, but researchers also documented mineral loss from teeth, since dental enamel and bone share the same underlying mineral: calcium and phosphate arranged in a crystal structure called hydroxyapatite.

This was a genuine, high stakes problem for a space agency planning increasingly long missions, and it set off a research effort within NASA to understand and eventually counter the effect. That broader context matters, because it explains why a NASA scientist working on a completely unrelated project would even think to connect his findings to tooth repair in the first place.

Bernard Rubin's Accidental Discovery

Bernard Rubin was not working on dental research when he made the discovery that eventually led to hydroxyapatite toothpaste. He was a scientist at NASA's Electronics Research Center in the late 1960s, working on crystal growth techniques relevant to semiconductor development, an area of research with no obvious connection to teeth at all. As Rubin's gel based crystals formed during this work, he noticed something that stopped him: the process closely resembled how bones and tooth enamel naturally grow their own mineral structure. The exact same calcium phosphate crystal that makes up dental enamel, hydroxyapatite, was forming under his lab conditions.

Rubin later told representatives from the first company to commercialize hydroxyapatite toothpaste that this realization was directly informed by his awareness of astronaut bone loss as one of the most serious physical effects of extended time in zero gravity. Given his background in materials science, he recognized what he was looking at and connected it to a problem NASA was actively worried about. Because hydroxyapatite is the primary mineral in both bone and tooth enamel, the same insight applied to both tissues.

The Patent That Sat Unused

Rubin and a fellow NASA scientist filed a patent in the early 1970s describing a method for growing crystals of brushite, a mineral precursor to hydroxyapatite, in a gel medium and then capping them onto the damaged surface of a tooth, where the material would convert into hydroxyapatite and repair the tooth directly. NASA's own retrospective describes this as an early example of biomimetics, the practice of imitating biological processes to solve biological problems, since the method was literally trying to replicate the tooth's own natural gel based mineral growth process rather than introducing something foreign to it.

The patent was granted in 1972. By that point, NASA's Electronics Research Center, where Rubin had done the original work, had already closed after only six years in operation, and Rubin himself had moved on. The idea that could have addressed a genuine astronaut health problem never made it into an actual spaceflight application. It existed only as an approved but entirely unused patent, sitting in NASA's records with no company or program actively pursuing it.

A Japanese Entrepreneur Finds It

This is the part of the story that turns a shelved government patent into a real product, and it happened almost by chance. In 1974, a Japanese entrepreneur named Shuji Sakuma was reviewing a list of available NASA patents, the kind of publicly accessible technology transfer listing NASA maintains specifically to let outside companies license government funded research. Rubin's hydroxyapatite patent caught his attention. Sakuma discussed the idea with an investor who had a background in dentistry, and in November 1974 he sent a dentist and a professor from Nippon Dental University to meet with Rubin directly to better understand the science before committing to it.

Sakuma's company, which would become Sangi Co., Ltd, purchased the rights to the patent, with sources placing the formal purchase in 1975. What followed was not an immediate product launch. Sangi spent several additional years refining Rubin's original concept into something that could actually function as a commercial toothpaste ingredient, running the necessary research and clinical work to move from a patented laboratory method to a real, testable, market ready formula.

Sangi Builds the First Hydroxyapatite Toothpaste

In 1980, Sangi released the world's first hydroxyapatite toothpaste onto the Japanese market. This was the first time the ingredient existed as an actual consumer product rather than a patent filing or a laboratory concept, roughly a decade after Rubin's original discovery and eight years after the underlying patent had been granted. Sangi's products have since expanded to be exported to dozens of countries, and the company more recently secured FDA approval for a hydroxyapatite formula marketed in the US specifically as an anti sensitivity toothpaste.

It is worth being precise about the timeline here, since some retellings of this story compress the dates in ways that overstate how quickly the science moved. Rubin's original insight came from late 1960s crystal research. The patent was filed in the early 1970s and granted in 1972. Sakuma discovered it in 1974 and purchased the rights around 1975. The first commercial toothpaste did not reach the market until 1980. That is roughly a decade between the original scientific observation and an actual product a consumer could buy, which is a genuinely long and unglamorous development timeline, not the instant space age breakthrough the shorter versions of this story sometimes imply.

Why Japan Adopted It Decades Before America

What happened next in Japan is arguably the more remarkable part of the story from a public health perspective. The Japanese Ministry of Health went on to officially designate hydroxyapatite as a recognized anti cavity ingredient, giving it the same regulatory standing that fluoride holds in most Western dental guidance. For more than four decades, hydroxyapatite toothpaste has been a mainstream, widely used option on Japanese pharmacy shelves, sitting alongside fluoride products rather than existing as a fringe alternative.

The United States took a very different path. American dentistry built its entire cavity prevention framework around fluoride starting in the mid 20th century, and hydroxyapatite remained largely unknown to US consumers and most US dentists for decades after Japan had already normalized it. It is a genuinely unusual situation in public health: a scientifically validated, government endorsed alternative to fluoride existed and had been in widespread daily use in a major developed country for over thirty years before it gained meaningful traction in the US market, a gap explained more by regulatory and market history than by any gap in the underlying science.

From Toothpaste to Nano Particle Size

The hydroxyapatite used in Sangi's original 1980 toothpaste and the nano hydroxyapatite used in modern remineralizing products are related but not identical. Advances in materials science over the following decades allowed manufacturers to produce hydroxyapatite at a specifically nano scale particle size, typically in the 20 to 100 nanometre range, which turned out to matter enormously for how the mineral actually functions on a tooth surface. Standard, larger hydroxyapatite particles are too big to penetrate the microscopic porosities in early demineralized enamel, meaning they mostly sit on top of the tooth and polish it. Nano sized particles are small enough to enter those same microporosities and deposit mineral directly where acid erosion has already begun to weaken the enamel structure, which is the mechanism behind the clinical remineralization and sensitivity reduction effects documented in modern research.

This nano particle size refinement is what separates the ingredient found in contemporary functional oral care products from the earlier, coarser hydroxyapatite formulas of the 1980s, and it is the version consistently referenced in the clinical literature: the 2023 meta analysis by Limeback, Enax, and Meyer, covering 44 clinical trials, specifically identified nano particle size as central to the ingredient's effect on reducing dentin hypersensitivity. The line from Rubin's original semiconductor lab crystal growth to a 20 to 100 nanometre particle depositing mineral into a real person's enamel today runs through more than fifty years of continued refinement, not a single moment of invention.

Where Dentagum Fits in This Lineage

Dentagum's use of nano hydroxyapatite sits directly in this fifty plus year lineage, from Rubin's original semiconductor lab observation, through Sangi's decade of Japanese market development, to the modern nano particle refinement that the current clinical evidence base is built around. Dentagum uses nano hydroxyapatite at 5 percent concentration, with particle sizes in the 20 to 100 nanometre range that the research consistently identifies as necessary for the ingredient to penetrate enamel microporosities and function as intended, rather than a generic or unspecified hydroxyapatite that may not carry the same clinical relevance.

This history matters beyond simple trivia. It explains why nano hydroxyapatite is not a recent wellness trend invented for marketing purposes, but a genuinely mature technology with a documented, verifiable origin story and more than four decades of real world use in at least one major developed country before it became widely available in the US. The ingredient's credibility does not rest on a clever brand narrative. It rests on an actual, traceable history involving a NASA patent, a Japanese entrepreneur, and a regulatory body on the other side of the world that made an official determination about the ingredient's value decades before most American consumers had ever heard of it.